Novo Nordisk (NYSE: NVO )
has long been one of the best-run, most-focused, and most-successful
specialty drug companies. It has also long been one of the most
expensive, as investors have happily paid up for clockwork growth,
leading share, and an excellent R&D enterprise.
The past year was an unusual one for Novo, though, as there were some
real setbacks in the company's operations. Those setbacks had the
shares trading for as close to "value" as it has in a long time, but the
30% run since November has these shares back at a premium valuation.
Follow this link for more:
Novo Nordisk A/S's Brief Value Run Seems Over
No comments:
Post a Comment